Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Singl...

FDA Recall #D-0126-2021 — Class II — December 8, 2020

Recall #D-0126-2021 Date: December 8, 2020 Classification: Class II Status: Terminated

Product Description

Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.

Reason for Recall

CGMP Deviations

Recalling Firm

Shilpa Medicare Limited — Polepally, Jadcherla, N/A

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

2008 vials

Distribution

Nationwide in the U.S.

Code Information

Lot #: 7S10185A, Exp. 10/31/2021

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated